Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Proof of Principle Program - Phase I

McGill University

$150,000.00

Identification of novel compounds inhibiting viral infections

FY 2008-09

Summary
Interferons constitute the fist line of defense against virus infection in most vertebrate animals. We previously reported that mice and cells lacking the proteins 4E-BP1 and 4E-BP2 were resistant to infection with a variety of viruses. We found that this resistance was due to increased production of interferon. Here, we propose to develop chemically modified SiRNA and small molecules which will eliminate or inactivate 4E-BPs function. We will screen for compounds which inhibit 4E-BPs activity. In addition, we will design SiRNAs that will decrease 4E-BPs levels. We predict that such compounds will boost the immunity of the organism and protect against Influenza virus and Human Immunodeficiency virus.
Program
Proof of Principle Program - Phase I
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
174449
Name
Sonenberg Nahum
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Identification of novel compounds inhibiting viral infections
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
4e Binding Proteins 1 And 2; High Throughput Screening For Inhibitors Of 4e-Bp1 And 2.; Immunology; Interferon; Knockout Mice; Viral Infections
Abstract
Interferons constitute the fist line of defense against virus infection in most vertebrate animals. We previously reported that mice and cells lacking the proteins 4E-BP1 and 4E-BP2 were resistant to infection with a variety of viruses. We found that this resistance was due to increased production of interferon. Here, we propose to develop chemically modified SiRNA and small molecules which will eliminate or inactivate 4E-BPs function. We will screen for compounds which inhibit 4E-BPs activity. In addition, we will design SiRNAs that will decrease 4E-BPs levels. We predict that such compounds will boost the immunity of the organism and protect against Influenza virus and Human Immunodeficiency virus.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sonenberg, Nahum
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $150,000~ $0~